mocetinostat

Mocetinostat is an orally bioavailable inhibitor of histone deacetylase (HDAC) enzymes. It primarily targets HDAC1 and HDAC2, which are enzymes involved in regulating gene expression by removing acetyl groups from histone proteins. This process can lead to chromatin condensation and transcriptional repression. By inhibiting HDAC1 and HDAC2, mocetinostat can promote the acetylation of histones, leading to a more relaxed chromatin structure and the potential re-activation of silenced genes.

The drug has been investigated for its potential in cancer therapy, particularly in hematological malignancies and solid tumors. The rationale behind its use stems from the observation that cancer cells often exhibit aberrant gene expression patterns, and HDAC inhibition can modulate these patterns, potentially leading to cell cycle arrest, differentiation, or apoptosis. Clinical trials have explored mocetinostat as a monotherapy and in combination with other anti-cancer agents. These trials have assessed its safety, tolerability, and preliminary efficacy in various cancer types, including lymphoma, leukemia, and pancreatic cancer. The development of mocetinostat is ongoing, with research continuing to define its optimal role in cancer treatment.